Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT

Published:October 29, 2021DOI:https://doi.org/10.1016/j.jinf.2021.10.024

      Highlights

      • The vast majority of HSCT recipients is eligible for HCV DAA-based treatment.
      • DAAs are safe and effective in HSCT recipients.
      • DAAs premature discontinuation was rare and not related to side effects.

      Abstract

      Objectives

      Limited data is available on HCV directly acting agents (DAAs) in haematopoietic stem cell transplant (HSCT) recipients. This study aimed at reporting the characteristics, treatment practices and treatment efficacy in HSCT recipients with chronic HCV.

      Methods

      Prospective observational study from EBMT Infectious Diseases Working Party (IDWP). Patients with chronic HCV infection were included.

      Results

      Between 12/2015 and 07/2018, 45 patients were included: male in 53%; median age 49 years (range, 8–75); acute leukaemia in 48.9%, lymphoma in 17.7%, non-malignant disorders in 22.3%; allogeneic HSCT in 84%; 77.8% no immunosuppressive treatment. Genotypes 1, 2, 3 and 4 were detected in 54.5%, 20.5%, 13.6% and 11.4%, respectively; advanced fibrosis in 40%, including cirrhosis in 11.4%. Overall, 37 (82.2%) patients received DAAs, at a median of 8.4 years after HSCT (16.2% within 6 months from HSCT). Sofosbuvir-based treatment was given to 62.2%. Thirty-five patients completed planned treatment course, with sustained virological response (SVR) of 89.1%, and 94.3% (33/35) in those who completed the treatment. Side effects possibly related to DAAs were reported in 5 (14%) and did not require treatment discontinuation.

      Conclusions

      DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HSCT recipients with mild/moderate liver damage.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • European Association for the Study of the Liver
        EASL recommendations on treatment of hepatitis C: final update of the series.
        J Hepatol. 2020; 73: 1170-1218
        • Gambato M.
        • Canini L.
        • Lens S.
        • Graw F.
        • Perpiñan E.
        • Londoño M.C.
        • et al.
        Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
        Liver Int Off J Int Assoc Study Liver. 2019; 39: 826-834
        • Torres H.A.
        • Chong P.P.
        • De Lima M.
        • Friedman M.S.
        • Giralt S.
        • Hammond S.P.
        • et al.
        Hepatitis C virus infection amongst hematopoietic cell transplant donors and recipients: American society for blood and marrow transplantation task force recommendations.
        Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015; 21: 1870-1882
        • Ljungman P.
        • Locasciulli A.
        • de Soria V.G.
        • Békássy A.N.
        • Brinch L.
        • Espigado I.
        • et al.
        Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy.
        Bone Marrow Transplant. 2012; 47: 1217-1221
        • Strasser S.I.
        • Sullivan K.M.
        • Myerson D.
        • Spurgeon C.L.
        • Storer B.
        • Schoch H.G.
        • et al.
        Cirrhosis of the liver in long-term marrow transplant survivors.
        Blood. 1999; 93: 3259-3266
        • Peffault de Latour R.
        • Lévy V.
        • Asselah T.
        • Marcellin P.
        • Scieux C.
        • Adès L.
        • et al.
        Long-term outcome of hepatitis C infection after bone marrow transplantation.
        Blood. 2004; 103: 1618-1624
        • Ivantes C.A.
        • Amarante H.
        • Ioshii S.O.
        • Pasquini R.
        Hepatitis C virus in long-term bone marrow transplant survivors.
        Bone Marrow Transplant. 2004; 33: 1181-1185
        • Castellino S.
        • Lensing S.
        • Riely C.
        • Rai S.N.
        • Davila R.
        • Hayden R.T.
        • et al.
        The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude children's research hospital hepatitis C seropositive cohort.
        Blood. 2004; 103: 2460-2466
        • Locasciulli A.
        • Testa M.
        • Valsecchi M.G.
        • Bacigalupo A.
        • Solinas S.
        • Tomas J.F.
        • et al.
        The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious disease working party of the European blood and marrow transplantation group.
        Transplantation. 1999; 68: 1486-1491
        • Lee C.C.
        • Chang H.H.
        • Lu M.Y.
        • Yang Y.L.
        • Chou S.W.
        • Lin D.T.
        • et al.
        The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.
        Ann Hematol. 2019; 98: 745-752
        • Evans A.T.
        • Loeb K.R.
        • Shulman H.M.
        • Hassan S.
        • Qiu W.C.
        • Hockenbery D.M.
        • et al.
        Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases.
        Am J Surg Pathol. 2015; 39: 212-220
        • Peffault de Latour R.
        • Asselah T.
        • Lévy V.
        • Scieux C.
        • Devergie A.
        • Ribaud P.
        • et al.
        Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.
        Bone Marrow Transplant. 2005; 36: 709-713
        • Mallet V.
        • van Bömmel F.
        • Doerig C.
        • Pischke S.
        • Hermine O.
        • Locasciulli A.
        • et al.
        Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).
        Lancet Infect Dis. 2016; 16: 606-617
      1. Ghany, M. G. and T. R. Morgan. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 71(2), 2020, 686-721.

        • Cunningham H.E.
        • Shea T.C.
        • Grgic T.
        • Lachiewicz A.M.
        Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant.
        Transplant Infect Dis Off J Transplant Soc. 2019; 21: e13091
        • Kyvernitakis A.
        • Mahale P.
        • Popat U.R.
        • Jiang Y.
        • Hosry J.
        • Champlin R.E.
        • et al.
        Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents.
        Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2016; 22: 717-722
        • Piñana J.L.
        • Serra M.
        • Hernández-Boluda J.C.
        • Navarro D.
        • Calabuig M.
        • Solano C.
        Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
        Transplant Infect Dis Off J Transplant Soc. 2016; 18: 89-92
        • Thomas P.
        • Santiago T.
        • Dallas M.H.
        Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation.
        Bone Marrow Transplant. 2016; 51: 735-737
        • E.E.E. European Association for the Study of the Liver. Electronic address, Clinical Clinical Practice Guidelines Panel, E.G.B. representative, Panel Members
        EASL recommendations on treatment of hepatitis C: final update of the series.
        J Hepatol. 2020; 73: 1170-1218
        • EASL-ALEH
        Clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.
        J Hepatol. 2015; 63: 237-264
        • Economides M.P.
        • Mahale P.
        • Kyvernitakis A.
        • Turturro F.
        • Kantarjian H.
        • Naing A.
        • et al.
        Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.
        Aliment Pharmacol Ther. 2016; 44: 1235-1241
        • Persico M.
        • Aglitti A.
        • Caruso R.
        • De Renzo A.
        • Selleri C.
        • Califano C.
        • et al.
        Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
        Hepatology. 2018; 67: 48-55
        • Merli M.
        • Frigeni M.
        • Alric L.
        • Visco C.
        • Besson C.
        • Mannelli L.
        • et al.
        Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas.
        Oncologist. 2019; 24: e720-e729
        • Arcaini L.
        • Besson C.
        • Frigeni M.
        • Fontaine H.
        • Goldaniga M.
        • Casato M.
        • et al.
        Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
        Blood. 2016; 128: 2527-2532
        • Alric L.
        • Besson C.
        • Lapidus N.
        • Jeannel J.
        • Michot J.M.
        • Cacoub P.
        • et al.
        Antiviral treatment of HCV-Infected patients with B-cell non-Hodgkin lymphoma: ANRS HC-13 Lympho-C study.
        PLoS One. 2016; 11e0162965
        • Martinot-Peignoux M.
        • Stern C.
        • Maylin S.
        • Ripault M.P.
        • Boyer N.
        • Leclere L.
        • et al.
        Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
        Hepatology. 2010; 51: 1122-1126
        • Sarrazin C.
        • Isakov V.
        • Svarovskaia E.S.
        • Hedskog C.
        • Martin R.
        • Chodavarapu K.
        • et al.
        Late relapse versus hepatitis c virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
        Clin Infect Dis Off Publ Infect Dis Soc Am. 2017; 64: 44-52
        • Johnson K.
        • Green P.K.
        • Ioannou G.N.
        Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
        J. Viral Hepat. 2017; 24: 966-975
        • Visco-Comandini U.
        • Lapa D.
        • Lionetti R.
        • Taibi C.
        • Loiacono L.
        • Montalbano M.
        • et al.
        Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
        J Med Virol. 2018; 90: 1264-1271
        • Hézode C.
        Why I do not treat patients for mild disease.
        Liver Int Off J Int Assoc Study Liver. 2016; 36: 13-20
        • Jara P.
        • Resti M.
        • Hierro L.
        • Giacchino R.
        • Barbera C.
        • Zancan L.
        • et al.
        Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children.
        Clin Infect Dis Off Publ Infect Dis Soc Am. 2003; 36: 275-280